Rheumatoid Arthritis Drugs Market Report

RA00748

Rheumatoid Arthritis Drugs Market, by Type (Pharmaceuticals, Biopharmaceuticals), Distribution Channel (Prescription, Over-the-Counter (OTC)): Global Opportunity Analysis and Industry Forecast, 2020-2027

RA00748

Pages: 240

Jan 2023

The global rheumatoid arthritis drugs market is estimated to surpass $70,580.8 million by 2027, exhibiting a CAGR of 2.5% from 2020 to 2027.

The report offers a thorough analysis of global rheumatoid arthritis drugs market with detailed study of various aspects of the market such as market dynamics, vital segments, major geographies, key players, and competitive landscape.

The report provides a clear picture of the current market situation and future trends of the global rheumatoid arthritis drugs market based on impact of various market dynamics and vital forces influencing the market. The drivers and opportunities in the market contributing to the market growth are acknowledged in the market dynamics. Besides, challenges and restraints that hold potential to hamper the market growth are also premeditated in the global rheumatoid arthritis drugs market. Porter’s five forces analysis is delivered through the report which precisely highlights the effects of key forces on the global rheumatoid arthritis drugs market.

The report offers market size and estimations analyzing global rheumatoid arthritis drugs market through various segments. In addition, the report includes geographical market analysis of these segments. Each segment entailed in the report is studied at regional and country level as well to provide complete coverage of global rheumatoid arthritis drugs market. The report categorizes the global rheumatoid arthritis drugs market into four major geographies including North America, Europe, Asia-Pacific, and LAMEA. These geographies are further sub-categorized into countries to cover rheumatoid arthritis drugs market scenario across in respective regions.

Furthermore, the report covers competitive scenario of the global rheumatoid arthritis drugs market. The key players operating in the global rheumatoid arthritis drugs market are studied in the report to understand their current market position and competitive strengths in the industry. The report profiles 10 key companies. Moreover, the company profiles include various data-points such as company overview, company executives, recent financials of the company, major growth strategies espoused by company, new initiatives and advancements by company to sustain and mend their position in the global rheumatoid arthritis drugs market, and others.

Research Methodology

We offer our clients comprehensive research and analysis based on an extensive variety of factual inputs, which mostly include industry participants’ interviews, reliable statistics, and regional acumen. The in-house market experts play an impactful role in designing analytic models and tools, personalized to the requirements of a market segment. These analytical models and tools sterilize the data and statistics and enrich the accuracy of our advice and recommendations.

For accomplishment of this research report, long hours of discussions and interviews have been conducted, with an extensive range of stakeholders that includes upstream and downstream participants. A number of product type literatures, annual reports, industry releases, and other related documents of key industry contributors have been reviewed, for better understanding of the market. We have executed a mix of primary and secondary research for the market estimates and forecasts. Secondary research formulae the initial phase of our detailed study, where we conduct wide-range data mining, referring to certified data sources such as technical journals, medical journals, independent studies, trade association’s releases, materials published by government and regulatory authorities.

KEY MARKET BENEFITS

The report is a compilation of detailed information, inputs from industry participants and industry experts across the value chain, and quantitative and qualitative assessment by industry analysts.

This report provides in-depth analysis of current market trends, governing factors, macro-economic indicators from 2019 to 2027 to identify & understand the prevailing opportunities and the strategic assessment of the growth of the global rheumatoid arthritis drugs market.

The report maps the qualitative sway of various industry factors on market segments as well as geographies.

The market estimations and size provided in the report are based on a comprehensive analysis of recent & futuristic key developments in the rheumatoid arthritis drugs market.

The growth and development strategies adopted by the prominent industry players are enlisted in the report to understand the competitive scenario of the rheumatoid arthritis drugs market.

KEY MARKET SEGMENTS

The global rheumatoid arthritis drugs market is segmented on the basis of following:

Type: Pharmaceuticals, Biopharmaceuticals

Distribution Channel: Prescription, Over-the-Counter (OTC)

Region: North America, Europe, Asia Pacific, and LAMEA.

This segment is further sub-segmented into the following regions:

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe

Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

LAMEA
- Brazil
- Argentina
- Saudi Arabia
- South Africa
- UAE
- Rest of LAMEA

KEY MARKET PLAYERS

The global rheumatoid arthritis drugs market is consolidated with the presence of large number of key players. These players focus upon innovation and expansion of product portfolios to acquire a competitive edge in the market space. The report summarizes various aspects of all these key players including financial performance, product portfolio, recent strategic moves & developments, and SWOT analysis.

Players in global rheumatoid arthritis drugs market include:

1. AbbVie Inc.

2. Boehringer Ingelheim GmbH

3. Novartis AG

4. Regeneron Pharmaceuticals, Inc.

5. Pfizer, Inc.

6. Johnson & Johnsons Services, Inc

7. Bristol-Myers Squibb Company

8. F. Hoffmann-La Roche Ltd.

9. Celegene Corporations

10. MedImmune, LLC

11. Amgen Inc.

1. RESEARCH METHODOLOGY
- 1.1. Desk Research
- 1.2. Real time insights and validation
- 1.3. Forecast model
- 1.4. Assumptions and forecast parameters
- 1.5. Market size estimation
  - 1.5.1. Top-down approach
  - 1.5.2. Bottom-up approach
2. REPORT SCOPE
- 2.1. Market definition
- 2.2. Key objectives of the study
- 2.3. Report overview
- 2.4. Market segmentation
- 2.5. Overview of the impact of COVID-19 on Global Rheumatoid Arthritis Drugs Market
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
- 4.1. Introduction
- 4.2. Growth impact forces
  - 4.2.1. Drivers
  - 4.2.2. Restraints
  - 4.2.3. Opportunities
- 4.3. Market value chain analysis
  - 4.3.1. List of raw material suppliers
  - 4.3.2. List of manufacturers
  - 4.3.3. List of distributors
- 4.4. Innovation & sustainability matrices
  - 4.4.1. Technology matrix
  - 4.4.2. Regulatory matrix
- 4.5. Porter’s five forces analysis
  - 4.5.1. Bargaining power of suppliers
  - 4.5.2. Bargaining power of consumers
  - 4.5.3. Threat of substitutes
  - 4.5.4. Threat of new entrants
  - 4.5.5. Competitive rivalry intensity
- 4.6. PESTLE analysis
  - 4.6.1. Political
  - 4.6.2. Economical
  - 4.6.3. Social
  - 4.6.4. Technological
  - 4.6.5. Environmental
- 4.7. Impact of COVID-19 on Rheumatoid Arthritis Drugs Market
  - 4.7.1. Pre-covid market scenario
  - 4.7.2. Post-covid market scenario
5. Rheumatoid Arthritis Drugs Market, By Product
- 5.1. Overview
- 5.2 Pharmaceuticals
  - 5.2.1 Definition, key trends, growth factors, and opportunities
  - 5.2.2 Market size analysis, by region, 2020-2027
  - 5.2.3 Market share analysis, by country, 2020-2027
- 5.3 Biopharmaceuticals
  - 5.3.1 Definition, key trends, growth factors, and opportunities
  - 5.3.2 Market size analysis, by region, 2020-2027
  - 5.3.3 Market share analysis, by country, 2020-2027
- 5.4 Research Dive Exclusive Insights
  - 5.4.1 Market attractiveness
  - 5.4.2 Competition heatmap
6. Rheumatoid Arthritis Drugs Market, By Location
- 6.1. Overview
- 6.2 Prescription
  - 6.2.1 Definition, key trends, growth factors, and opportunities
  - 6.2.2 Market size analysis, by region, 2020-2027
  - 6.2.3 Market share analysis, by country, 2020-2027
- 6.3 Over-the-Counter (OTC)
  - 6.3.1 Definition, key trends, growth factors, and opportunities
  - 6.3.2 Market size analysis, by region, 2020-2027
  - 6.3.3 Market share analysis, by country, 2020-2027
- 6.4 Research Dive Exclusive Insights
  - 6.4.1 Market attractiveness
  - 6.4.2 Competition heatmap
7. Rheumatoid Arthritis Drugs Market, By Region
- 7.1 North America
  - 7.1.1 U.S
    - 7.1.1.1 Market size analysis, By Product, 2020-2027
    - 7.1.1.2 Market size analysis, By Location, 2020-2027
  - 7.1.2 Canada
    - 7.1.2.1 Market size analysis, By Product, 2020-2027
    - 7.1.2.2 Market size analysis, By Location, 2020-2027
  - 7.1.3 Mexico
    - 7.1.3.1 Market size analysis, By Product, 2020-2027
    - 7.1.3.2 Market size analysis, By Location, 2020-2027
  - 7.1.4 Research Dive Exclusive Insights
    - 7.1.4.1 Market attractiveness
    - 7.1.4.2 Competition heatmap
- 7.2 Europe
  - 7.2.1 Germany
    - 7.2.1.1 Market size analysis, By Product, 2020-2027
    - 7.2.1.2 Market size analysis, By Location, 2020-2027
  - 7.2.2 UK
    - 7.2.2.1 Market size analysis, By Product, 2020-2027
    - 7.2.2.2 Market size analysis, By Location, 2020-2027
  - 7.2.3 France
    - 7.2.3.1 Market size analysis, By Product, 2020-2027
    - 7.2.3.2 Market size analysis, By Location, 2020-2027
  - 7.2.4 Spain
    - 7.2.4.1 Market size analysis, By Product, 2020-2027
    - 7.2.4.2 Market size analysis, By Location, 2020-2027
  - 7.2.5 Italy
    - 7.2.5.1 Market size analysis, By Product, 2020-2027
    - 7.2.5.2 Market size analysis, By Location, 2020-2027
  - 7.2.6 Rest of Europe
    - 7.2.6.1 Market size analysis, By Product, 2020-2027
    - 7.2.6.2 Market size analysis, By Location, 2020-2027
  - 7.2.7 Research Dive Exclusive Insights
    - 7.2.7.1 Market attractiveness
    - 7.2.7.2 Competition heatmap
- 7.3 Asia-Pacific
  - 7.3.1 China
    - 7.3.1.1 Market size analysis, By Product, 2020-2027
    - 7.3.1.2 Market size analysis, By Location, 2020-2027
  - 7.3.2 Japan
    - 7.3.2.1 Market size analysis, By Product, 2020-2027
    - 7.3.2.2 Market size analysis, By Location, 2020-2027
  - 7.3.3 India
    - 7.3.3.1 Market size analysis, By Product, 2020-2027
    - 7.3.3.2 Market size analysis, By Location, 2020-2027
  - 7.3.4 Australia
    - 7.3.4.1 Market size analysis, By Product, 2020-2027
    - 7.3.4.2 Market size analysis, By Location, 2020-2027
  - 7.3.5 South Korea
    - 7.3.5.1 Market size analysis, By Product, 2020-2027
    - 7.3.5.2 Market size analysis, By Location, 2020-2027
  - 7.3.6 Rest of Asia-Pacific
    - 7.3.6.1 Market size analysis, By Product, 2020-2027
    - 7.3.6.2 Market size analysis, By Location, 2020-2027
  - 7.3.7 Research Dive Exclusive Insights
    - 7.3.7.1 Market attractiveness
    - 7.3.7.2 Competition heatmap
- 7.4 LAMEA
  - 7.4.1 Brazil
    - 7.4.1.1 Market size analysis, By Product, 2020-2027
    - 7.4.1.2 Market size analysis, By Location, 2020-2027
  - 7.4.2 Saudi Arabia
    - 7.4.2.1 Market size analysis, By Product, 2020-2027
    - 7.4.2.2 Market size analysis, By Location, 2020-2027
  - 7.4.3 UAE
    - 7.4.3.1 Market size analysis, By Product, 2020-2027
    - 7.4.3.2 Market size analysis, By Location, 2020-2027
  - 7.4.4 South Africa
    - 7.4.4.1 Market size analysis, By Product, 2020-2027
    - 7.4.4.2 Market size analysis, By Location, 2020-2027
  - 7.4.5 Rest of LAMEA
    - 7.4.5.1 Market size analysis, By Product, 2020-2027
    - 7.4.5.2 Market size analysis, By Location, 2020-2027
  - 7.4.6 Research Dive Exclusive Insights
    - 7.4.6.1 Market attractiveness
    - 7.4.6.2 Competition heatmap
8. Competitive Landscape
- 8.1 Top winning strategies, 2020-2027
  - 8.1.1 By strategy
  - 8.1.2 By year
- 8.2 Strategic overview
- 8.3 Market share analysis, 2020-2027
9. Company Profiles
- 9.1 AbbVie Inc.
  - 9.1.1 Overview
  - 9.1.2 Business segments
  - 9.1.3 Product portfolio
  - 9.1.4 Financial performance
  - 9.1.5 Recent developments
  - 9.1.6 SWOT analysis
- 9.2 Boehringer Ingelheim GmbH
  - 9.2.1 Overview
  - 9.2.2 Business segments
  - 9.2.3 Product portfolio
  - 9.2.4 Financial performance
  - 9.2.5 Recent developments
  - 9.2.6 SWOT analysis
- 9.3 Novartis AG
  - 9.3.1 Overview
  - 9.3.2 Business segments
  - 9.3.3 Product portfolio
  - 9.3.4 Financial performance
  - 9.3.5 Recent developments
  - 9.3.6 SWOT analysis
- 9.4 Regeneron Pharmaceuticals, Inc.
  - 9.4.1 Overview
  - 9.4.2 Business segments
  - 9.4.3 Product portfolio
  - 9.4.4 Financial performance
  - 9.4.5 Recent developments
  - 9.4.6 SWOT analysis
- 9.5 Pfizer, Inc.
  - 9.5.1 Overview
  - 9.5.2 Business segments
  - 9.5.3 Product portfolio
  - 9.5.4 Financial performance
  - 9.5.5 Recent developments
  - 9.5.6 SWOT analysis
- 9.6 Johnson & Johnsons Services, Inc
  - 9.6.1 Overview
  - 9.6.2 Business segments
  - 9.6.3 Product portfolio
  - 9.6.4 Financial performance
  - 9.6.5 Recent developments
  - 9.6.6 SWOT analysis
- 9.7 Bristol-Myers Squibb Company
  - 9.7.1 Overview
  - 9.7.2 Business segments
  - 9.7.3 Product portfolio
  - 9.7.4 Financial performance
  - 9.7.5 Recent developments
  - 9.7.6 SWOT analysis
- 9.8 F. Hoffmann-La Roche Ltd.
  - 9.8.1 Overview
  - 9.8.2 Business segments
  - 9.8.3 Product portfolio
  - 9.8.4 Financial performance
  - 9.8.5 Recent developments
  - 9.8.6 SWOT analysis
- 9.9 Celegene Corporations
  - 9.9.1 Overview
  - 9.9.2 Business segments
  - 9.9.3 Product portfolio
  - 9.9.4 Financial performance
  - 9.9.5 Recent developments
  - 9.9.6 SWOT analysis
- 9.10 MedImmune, LLC
  - 9.10.1 Overview
  - 9.10.2 Business segments
  - 9.10.3 Product portfolio
  - 9.10.4 Financial performance
  - 9.10.5 Recent developments
  - 9.10.6 SWOT analysis
- 9.11 Amgen Inc.
  - 9.11.1 Overview
  - 9.11.2 Business segments
  - 9.11.3 Product portfolio
  - 9.11.4 Financial performance
  - 9.11.5 Recent developments
  - 9.11.6 SWOT analysis

Purchase Options

Individual License $4290 Corporate License $4920

Personalize this research

Triangulate with your own data
Request your format and definition
Get a deeper dive on a specific application, geography, customer or competitor

10% Off on Customization

Speak To The Analyst
Or Schedule A Call

+ 1-888-961-4454 Toll - Free
support@researchdive.com

Rheumatoid Arthritis Drugs Market Report

Rheumatoid Arthritis Drugs Market, by Type (Pharmaceuticals, Biopharmaceuticals), Distribution Channel (Prescription, Over-the-Counter (OTC)): Global Opportunity Analysis and Industry Forecast, 2020-2027

1. RESEARCH METHODOLOGY

1.1. Desk Research

1.2. Real time insights and validation

1.3. Forecast model

1.4. Assumptions and forecast parameters

1.5. Market size estimation

1.5.1. Top-down approach

1.5.2. Bottom-up approach

2. REPORT SCOPE

2.1. Market definition

2.2. Key objectives of the study

2.3. Report overview

2.4. Market segmentation

2.5. Overview of the impact of COVID-19 on Global Rheumatoid Arthritis Drugs Market

3. EXECUTIVE SUMMARY

4. MARKET OVERVIEW

4.1. Introduction

4.2. Growth impact forces

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunities

4.3. Market value chain analysis

4.3.1. List of raw material suppliers

4.3.2. List of manufacturers

4.3.3. List of distributors

4.4. Innovation & sustainability matrices

4.4.1. Technology matrix

4.4.2. Regulatory matrix

4.5. Porter’s five forces analysis

4.5.1. Bargaining power of suppliers

4.5.2. Bargaining power of consumers

4.5.3. Threat of substitutes

4.5.4. Threat of new entrants

4.5.5. Competitive rivalry intensity

4.6. PESTLE analysis

4.6.1. Political

4.6.2. Economical

4.6.3. Social

4.6.4. Technological

4.6.5. Environmental

4.7. Impact of COVID-19 on Rheumatoid Arthritis Drugs Market

4.7.1. Pre-covid market scenario

4.7.2. Post-covid market scenario

5. Rheumatoid Arthritis Drugs Market, By Product

5.1. Overview

5.2 Pharmaceuticals

5.2.1 Definition, key trends, growth factors, and opportunities

5.2.2 Market size analysis, by region, 2020-2027

5.2.3 Market share analysis, by country, 2020-2027

5.3 Biopharmaceuticals

5.3.1 Definition, key trends, growth factors, and opportunities

5.3.2 Market size analysis, by region, 2020-2027

5.3.3 Market share analysis, by country, 2020-2027

5.4 Research Dive Exclusive Insights

5.4.1 Market attractiveness

5.4.2 Competition heatmap

6. Rheumatoid Arthritis Drugs Market, By Location

6.1. Overview

6.2 Prescription

6.2.1 Definition, key trends, growth factors, and opportunities

6.2.2 Market size analysis, by region, 2020-2027

6.2.3 Market share analysis, by country, 2020-2027

6.3 Over-the-Counter (OTC)

6.3.1 Definition, key trends, growth factors, and opportunities

6.3.2 Market size analysis, by region, 2020-2027

6.3.3 Market share analysis, by country, 2020-2027

6.4 Research Dive Exclusive Insights

6.4.1 Market attractiveness

6.4.2 Competition heatmap

7. Rheumatoid Arthritis Drugs Market, By Region

7.1 North America

7.1.1 U.S

7.1.1.1 Market size analysis, By Product, 2020-2027

7.1.1.2 Market size analysis, By Location, 2020-2027

7.1.2 Canada

7.1.2.1 Market size analysis, By Product, 2020-2027

7.1.2.2 Market size analysis, By Location, 2020-2027

7.1.3 Mexico